Develops topical therapies for inflammatory skin diseases, aiming to provide effective treatments with minimal systemic side effects.
Forte Biosciences, Inc. is a dynamic clinical-stage biopharmaceutical firm based in the United States, specializing in innovative treatments for autoimmune diseases. At the forefront of its development pipeline is the FB-102 program, designed to target conditions like vitiligo and alopecia areata, which significantly impact patients' quality of life. The company's pioneering research and therapeutic focus underscore its commitment to advancing novel treatments in dermatology and autoimmune disorders.
Headquartered in Dallas, Texas, Forte Biosciences operates with a mission to address unmet medical needs through cutting-edge biopharmaceutical innovations. The company's strategic location in a hub of medical innovation supports its efforts to bring transformative therapies to patients suffering from autoimmune conditions. With a dedicated team and a strong clinical pipeline, Forte Biosciences is poised to make significant strides in the field of autoimmune disease treatment.
Founded on a foundation of scientific excellence and patient-centered innovation, Forte Biosciences continues to expand its capabilities and partnerships. By leveraging its expertise in dermatology and autoimmune research, the company aims to deliver meaningful advancements that improve the lives of patients worldwide.